Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01719783
Other study ID # LAIV-H5N2-01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 2012
Est. completion date January 2013

Study information

Verified date November 2018
Source PATH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety profile of two intranasal doses of LAIV A/17/turkey/Turkey/05/133 (H5N2) in healthy adults.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date January 2013
Est. primary completion date January 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria:

- Legal male or female adult 18 through 49 years of age at the enrollment visit.

- Literate and willing to provide written informed consent.

- Free of obvious health problems, as established by the medical history and screening evaluations, including physical examination.

- Capable and willing to complete diary cards and willing to return for all follow-up visits

- Willing to comply with the rules of the isolation unit (including willing and able to take oseltamivir influenza antiviral medication, should that be recommended by a study physician).

- For females, willing to take reliable birth control measures throughout the entire period of participation in the study.

Exclusion Criteria:

- Participation in another clinical trial involving any therapy within the previous three months or planned enrollment in such a trial during the period of this study.

- Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to postpone receipt of such vaccines until four weeks after study completion.

- Practice of nasal irrigation on a regular basis within the past six months or has engaged in nasal irrigation within two weeks prior to enrollment.

- Recent history of frequent nose bleeds (>5 within the past year).

- Clinically relevant abnormal paranasal anatomy.

- Recent history (within the past month) of rhino or sinus surgery, or surgery for any traumatic injury of the nose.

- Current or recent (within two weeks of enrollment) acute respiratory illness with or without fever.

- Other acute illness at the time of study enrollment.

- Receipt of immune globulin or other blood products within three months prior to study enrollment or planned receipt of such products during the period of subject participation in the study.

- Chronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants or other immune-modulating therapy within six months prior to study enrollment. (For corticosteroids, this means prednisone or equivalent, 0.5 mg per kg per day; topical steroids are allowed, exclusive of nasal.)

- Participation in any previous trial of any H5 or H7 containing influenza vaccine.

- History of asthma.

- Hypersensitivity after previous administration of any influenza vaccine.

- History of wheezing after past receipt of any live influenza vaccine.

- Other adverse event (AE) following immunization, at least possibly related to previous receipt of any influenza vaccine.

- Suspected or known hypersensitivity to any of the study vaccine components, including chicken or egg protein.

- Seasonal (autumnal) hypersensitivity to the natural environment.

- Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, metabolic, neurologic, psychiatric or renal functional abnormality, as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives. Subjects with physical examination findings or clinical laboratory screening results which would be graded 2 or higher on the AE severity grading scale (see Attachments) will be excluded from entry into the study and will be excluded from receipt of dose two of study vaccine or placebo.

- History of leukemia or any other blood or solid organ cancer.

- History of thrombocytopenic purpura or known bleeding disorder.

- History of seizures.

- Known or suspected immunosuppressive or immunodeficient condition of any kind, including HIV infection.

- Known chronic hepatitis B (HBV) or hepatitis C (HCV) infection.

- Known tuberculosis infection or evidence of previous tuberculosis exposure.

- History of chronic alcohol abuse and/or illegal drug use.

- Claustrophobia or sociophobia.

- Pregnancy or lactation. (A negative pregnancy test will be required before administration of study vaccine or placebo for all women of childbearing potential.)

- Any condition that, in the opinion of the investigator, would increase the health risk to the subject if he/she participates in the study or would interfere with the evaluation of the study objectives

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
LAIV H5N2
2 doses provided intranasally
Other:
Placebo
2 doses of placebo provided intranasally

Locations

Country Name City State
Russian Federation Research Institute of Influenza St. Petersburg

Sponsors (3)

Lead Sponsor Collaborator
PATH Institute of Experimental Medicine, Russia, Microgen Scientific Industrial Company for Immunobiological Medicines

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Other Number/Percentage of Subjects Exhibiting CD8+ IFN?+ Responses Nasal swabs from days 1, 2, 3, 5, and 7 after the first vaccination and on days 1 and 3, corresponding to days 29 and 31,respectively, after the second dose were tested for viral shedding by inoculation in 10- to 11-day-old embryonated chicken eggs (ECE) followed by incubation at 32?C for 72 h. Influenza virus was detected by standard hemagglutination test with 1% chicken red blood cells.
An increase in the number of antigenic-specific T cells greater than 3 standard deviations over the mean placebo values was regarded as a positive T cell response.
28 days (Dose 1) and 56 days (Dose 2)
Other Number/Percentage of Subjects Exhibiting CD4+ IFN?+ Responses Nasal swabs from days 1, 2, 3, 5, and 7 after the first vaccination and on days 1 and 3, corresponding to days 29 and 31,respectively, after the second dose were tested for viral shedding by inoculation in 10- to 11-day-old ECE followed by incubation at 32?C for 72 h. Influenza virus was detected by standard hemagglutination test with 1% chicken red blood cells.
An increase in the number of antigenic-specific T cells greater than 3 standard deviations over the mean placebo values was regarded as a positive T cell response.
28 days (Dose 1) and 56 days (Dose 2)
Other Number/Percentage of Subjects Exhibiting CD8+ IFN?+ Effector Memory T Cell Responses Nasal swabs from days 1, 2, 3, 5, and 7 after the first vaccination and on days 1 and 3, corresponding to days 29 and 31,respectively, after the second dose were tested for viral shedding by inoculation in 10- to 11-day-old ECE followed by incubation at 32?C for 72 h. Influenza virus was detected by standard hemagglutination test with 1% chicken red blood cells.
An increase in the number of antigenic-specific T cells greater than 3SD over the mean placebo values was regarded as a positive T cell response.
28 days (Dose 1) and 56 days (Dose 2)
Other Number/Percentage of Subjects Exhibiting CD4+ IFN?+ Central Memory T Cell Responses Nasal swabs from days 1, 2, 3, 5, and 7 after the first vaccination and on days 1 and 3, corresponding to days 29 and 31,respectively, after the second dose were tested for viral shedding by inoculation in 10- to 11-day-old ECE followed by incubation at 32?C for 72 h. Influenza virus was detected by standard hemagglutination test with 1% chicken red blood cells.
An increase in the number of antigenic-specific T cells greater than 3SD over the mean placebo values was regarded as a positive T cell response.
28 days (Dose 1) and 56 days (Dose 2)
Other Number/Percentage of Subjects Exhibiting CD4+ IFN?+ Effector Memory T Cell Responses Nasal swabs from days 1, 2, 3, 5, and 7 after the first vaccination and on days 1 and 3, corresponding to days 29 and 31,respectively, after the second dose were tested for viral shedding by inoculation in 10- to 11-day-old ECE followed by incubation at 32?C for 72 h. Influenza virus was detected by standard hemagglutination test with 1% chicken red blood cells.
An increase in the number of antigenic-specific T cells greater than 3SD over the mean placebo values was regarded as a positive T cell response.
28 days (Dose 1) and 56 days (Dose 2)
Other Number/Percentage of Subjects Exhibiting CD8+ IFN?+ Central Memory T Cell Responses Nasal swabs from days 1, 2, 3, 5, and 7 after the first vaccination and on days 1 and 3, corresponding to days 29 and 31,respectively, after the second dose were tested for viral shedding by inoculation in 10- to 11-day-old ECE followed by incubation at 32?C for 72 h. Influenza virus was detected by standard hemagglutination test with 1% chicken red blood cells.
An increase in the number of antigenic-specific T cells greater than 3SD over the mean placebo values was regarded as a positive T cell response.
28 days (Dose 1) and 56 days (Dose 2)
Primary Adverse Events by Severity Occurrence of participants with adverse events associated with intranasal administration, by worst grade of severity 6 days
Secondary Number/Percentage of Subjects With Seroconversion for Serum Hemagglutination Inhibition (HAI) Defined as a four-fold or greater antibody rise in titer from pre-vaccination level.
HAI = hemagglutination-inhibition, conducted using World Health Organization (WHO)-recommended protocols.
28 days (Dose 1) and 56 days (Dose 2)
Secondary Number/Percentage of Subjects With Serum Neutralizing Antibodies Defined as a four-fold or greater antibody rise in titer from pre-vaccination level.
Measured by microneutralization assay in Madin-Darby canine kidney cells (MDCK).
28 days (Dose 1) and 56 days (Dose 2)
Secondary Number/Percentage of Subjects With Seroconversion for Serum Immunoglobulin A (IgA) IgA = immunoglobulin class A antibodies Determined using ELISA using whole purified H5N2 28 days (Dose 1) and 56 days (Dose 2)
Secondary Number/Percentage of Subjects With Seroconversion for Serum Immunoglobulin G (IgG) Determined using ELISA using whole purified H5N2. 28 days (Dose 1) and 56 days (Dose 2)
Secondary Number/Percentage of Subjects With Seroconversion for Secretory IgA IgA antibodies from the nasal mucosa detected in nasal wick specimens. Determined using ELISA using whole purified H5N2 28 days (Dose 1) and 56 days (Dose 2)
Secondary Number/Percentage of Subjects With Seroconversion for IgA in Saliva IgA = Immunoglobulin Class A antibodies. Determined using ELISA using whole purified H5N2. 28 days (Dose 1) and 56 days (Dose 2)
Secondary Number/Percentage of Vaccinated Participants Shedding Influenza Virus After First Dose Nasal swabs were collected and used for Reverse transcription polymerase chain reaction (rRTPCR) assays to detect shedding of influenza virus for days 1-6 of the study. 6 days post-vaccination
Secondary Number/Percentage of Vaccinated Participants Shedding Influenza Virus After Second Dose Nasal swabs were collected and used for Reverse transcription polymerase chain reaction (rRTPCR) assays to detect shedding of influenza virus for days 29-34 of the study (6 days after the second vaccination). 6 days post-vaccination
Secondary Geometric Mean Titers for Serum HAI Antibodies Geometric mean titers for serum hemagglutination inhibition antibodies 0 days, 28 days (Dose 1) and 56 days (Dose 2)
Secondary Geometric Mean Titers (GMT) for Serum Neutralizing Antibodies Geometric mean titers for serum neutralizing antibodies measured by microneutralization assay 0 days, 28 days (Dose 1) and 56 days (Dose 2)
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A